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Abstract
Background: NORE1A and RASSF1A are growth and tumour suppressors inactivated in a variety of cancers. Methylation of
NORE1A and RASSF1A promoters is the predominant mechanism for downregulation of these proteins; however, other
mechanisms are likely to exist.
Methodology/Principal Findings: Here we describe a proteolysis of NORE1A and RASSF1A by calpains as alternative
mechanism of their downregulation. Extracts of H358 cell line, a human bronchoalveolar carcinoma, and H460, a large cell
carcinoma, were capable of proteolysis of NORE1A protein in the calpain-dependent manner. Likewise, RASSF1A tumor
suppressor was proteolyzed by the H358 cell extract. Addition of calpain inhibitor to H358 and H460 cells growing in tissue
culture resulted in re-expression of endogenous NORE1A. A survey of 10 human lung tumours revealed that three of them
contain an activity capable of inducing NORE1A degradation.
Conclusions/Significance: Thus, degradation by calpains is a novel mechanism for downregulation of NORE1A and
RASSF1A proteins and might be the mechanism allowing cancer cells to escape growth suppression.
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Introduction
The NORE1A protein was identified in a yeast two-hybrid
screen as a putative Ras effector that binds Ras protein in a GTP-
dependent manner [1]. The full-length NORE1A cDNA encodes
a 47-kDa basic protein that has a proline-rich N-terminus and a
cysteine-rich domain that is homologous to the C1 domains of
PKC and Raf. Its Ras-association (RA) domain is located centrally
[2]. In contrast to the well-known Ras pathways promoting
proliferation and oncogenesis, NORE1A mediates growth sup-
pression. NORE1A is expressed in most normal tissues but is lost
in cancer (see [3] for review). NORE1A downregulation in cancer
appears to be due to hypermethylation of its promoter CpG
islands [4,5]. Reconstitution of NORE1A expression induces
growth arrest as well as cell death in a variety of tumor cell lines
[6–8].
Ras-association domain family 1 (RASSF1) was discovered as a
tumor suppressor gene located on human chromosome 3p21 in a
segment that is deleted in many human solid tumors [9].
Expression of the longest splice isoform of the RASSF1 gene,
RASSF1A, is downregulated by selective hypermethylation of its
promoter CpG islands in at least 37 tumour types, according to the
recent review [3]. RASSF1A is thought to be the most frequently
methylated gene described in human cancers so far [10].
RASSF1A is the closest relative to NORE1A (41% identity at
the amino acid level); it is also capable of binding to activated Ras
[2]. Re-expression of RASSF1A in various tumour cell lines where
this gene was deleted or its promoter is methylated inhibits cell
growth, invasion, stimulates apoptosis and reduces tumorigenicity
in mouse models [11,12]. Targeted disruption of the RASSF1A
gene increases spontaneous tumorigenesis. The exposure of
RASSF1A-null mice to physical and chemical mutagens and
carcinogens increased tumour susceptibility relative to controls
[13,14].
Although the promoter methylation is apparently the major
mechanism of silencing of NORE1A and RASSF1A expression,
other mechanisms likely exists. NORE1A expresses in human
adrenal medulla while its expression was lost in pheochromocy-
toma and abdominal paraganglioma tumors. The NORE1A
promoter in these tumors was not methylated but no mRNA
expression was detected. In addition, both NORE1A mRNA and
protein levels are severely downregulated in follicular thyroid
carcinomas harboring a PAX8-PPARc translocation; however, the
NORE1A promoter was not methylated [15]. Recent studies
suggested that up to 15% of tumors may contain inactivating point
mutations in RASSF1A [16].
In the current study, we describe that NORE1A and
RASSF1A proteins undergo a proteolytic cleavage by an activity
present in extracts of several human tumor cell lines. This
proteolytic activity was sensitive to inhibitors of proteases called
calpains. A survey of 10 human lung cancer samples revealed
that at least three of them also contains an activity capable of
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3997
proteolyzing NORE1A. Thus, calpain-mediated degradation
could be a novel mechanism of inactivation NORE1A and
RASSF1A in cancers.
Results
NORE1A and RASSF1A proteins are proteolyzed by an
activity present in extract of some human tumor cell
lines
We found that incubation of NORE1A protein for 30 minutes
at 37uC with extracts of human lung cancer cell lines H358
(bronchoalveolar carcinoma) and H460 (large cell carcinoma)
resulted in proteolysis of the NORE1A protein (Figure 1, lanes 2
and 3). The RASSF1A tumor suppressor was proteolyzed by the
H358 cell extract (Fig. 1, lane 6) but not H460 cell extract (Fig. 1,
lane 7). Cell extracts of A549 lung adenocarcinoma cells (Fig. 1,
lanes 4 and 8), normal human bronchial cells, normal human
fibroblasts, HEK293 cells, H157 squamous cell carcinoma and
SW1573 lung alveolar carcinoma cells (data not shown) were
devoid of this proteolytic activity.
Mapping of cleavage sites within NORE1A
Experiments with the proteolysis of NORE1A fragments
suggested that it might occur within the first 190 amino acids of
the protein (Figure 2A). This region contains Proline-rich region
(aa 1–119) and the Cysteine-rich C1 domain (aa 120–166)
potentially involved in lipid binding [17]. Attempts to map the
cleavage site(s) more precisely suggested that the cleavage occurs
after position 78 in NORE1A in the Proline-rich region, since
NORE1A fragment 78–190 is cleaved by H358 cell extract
(Figure 2B, lane 6).
Cleavage of NORE1A and RASSF1A by tumor cell extracts
requires calcium ions and is prevented by a calpain
inhibitor
Since the N-terminus of NORE1A is reach in prolines, we
hypothesized that calpains, a class of proteases which have
preference to Proline-rich sequences, might be responsible for its
cleavage. Indeed, addition of a broad-spectrum calpain inhibitor,
ALLN (N-Acetyl-Leu-Leu-Nle-CHO), to the extract of H358 cells
completely inhibited NORE1A (Figure 3A, lane 3) and RASSF1A
(Figure 3A, lane 7) proteolysis.
Calpains are calcium-dependent proteases. As shown on
Figure 3A, lanes 4 and 8, chelation of calcium ions by addition
of EDTA inhibited cleavage of NORE1A and RASSF1A by H358
cell lysate, consisting with the hypothesis that calpains are
responsible for the cleavage.
The ALLN compound is not specific for calpains: it could also
inhibit Cathepsin B and Cathepsin K proteases. However, as
shown on Figure 3B, the addition of Cathepsin B and Cathepsin K
inhibitors did not prevent NORE1 cleavage by lysates of H358
(lanes 4, 5) and H460 (lanes 8, 9) cells. The requirement of Ca2+
ions for NORE1A and RASSF1A cleavage also argues against
cathepsins B and K involvement, since they are not calcium-
dependent proteases.
Inhibition of calpain in cultured H358 and H460 tumor
cells results in re-expression of NORE1A protein
NORE1A and RASSF1A are not expressed in H358 and H460
cells at the protein level [6,8,18]. Our attempts to stably express
NORE1A protein in H358 and H460 cells using a retroviral or
plasmid vector with the drug-resistance marker resulted in drug-
Figure 1. Cleavage of NORE1A and RASSF1A by an activity
expressed in some tumor cell lines. Full-length NORE1A and
RASSF1A, tagged at the N-terminus with the FLAG tag, were expressed
in HEK293 cells, immunopurified on FLAG beads and beads were eluted
with FLAG-peptide. NORE1A (lanes 1–4) or RASSF1A (lanes 5–8) were
incubated with the Buffer A (lanes 1, 5) or H358 cell lysate (lanes 2, 6), or
H460 cell lysates (lanes 3, 7), or A549 cell lysates (lanes 4, 8) for
30 minutes at 37uC. After incubation, samples were subjected to gel
electrophoresis followed by Western blotting with anti-FLAG antibod-
ies.
doi:10.1371/journal.pone.0003997.g001
Figure 2. NORE1A cleavage occurs at the N-terminus of the
protein. A: Full-length NORE1A (lanes 1, 2) or its fragments aa 1–364
(lanes 3, 4) or aa 1–190 (lanes 5, 6), tagged N-terminally with the FLAG
tag, immunopurified as described in Figure 1, were incubated with the
lysis buffer (lanes 1, 3, 5) or with H358 cell lysate (lanes 2, 4, 6) for
30 minutes at 37uC. After incubation, samples were subjected to gel
electrophoresis followed by Western blotting with anti-FLAG antibod-
ies. Asterisks denote non-specific bands. B: NORE1A fragments, amino
acids 18–190, 43–190 and 78–190 were synthesized in vitro using
Promega TnT T7 Quick for PCR DNA kit in the presence of 35S-
Methionine. Each fragment contained an additional methionine as start
codon and two extra methionines at the C-terminus to facilitate
detection. An aliquot of translation mixture was incubated with 46
excess (v/v) of H358 cell extract or with Buffer A for 1 hour at 37uC,
resolved on SDS gel and transferred to Immobilon. Shown is the
autoradiogram of the membrane obtained by Phosphoimager.
doi:10.1371/journal.pone.0003997.g002
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resistant cell populations that have little or no expression of the
full-length NORE1A protein detectable by Western blotting
(Figure 4A, lanes 3 and 5). However, the NORE1A mRNA
message was readily detected by reverse transcription-polymerase
chain reaction (RT-PCR) in such drug-resistant cells (Fig. 4B). We
suggested that the reason for this might be proteolysis of NORE1A
by calpains in H358 and H460 cell lines. Indeed, when H358 and
H460 cells transfected with NORE1A-expressing plasmid were
propagated in tissue culture in the presence of a calpain inhibitor,
a prominent NORE1A band appeared on Western blots
(Figure 4A, lanes 8 and 10). Moreover, a weaker band with the
mobility of NORE1A appeared in lysates of parental H358 and
H460 cells, propagated in the presence of a calpain inhibitor,
suggesting that inhibition of calpains resulted in re-expression of
endogenous NORE1A in these lung cancer cell lines (Figure 4A,
lanes 7 and 9).
Extracts of some human tumors are capable of NORE1A
cleavage
To determine whether human tumors may contain an activity
that cleaves NORE1A, we examined extracts from ten lung
cancers and matching non-tumor tissues form the same patient
to cleave FLAG-NORE1A in vitro. As shown on Figure 4C,
extracts from tumors taken from patients 3, 9 and 10 were
capable of inducing NORE1A cleavage and degradation (lanes
4, 6 and 8) while extract from tumor taken from patient 8 (lane
10), as well as extracts taken from six other patients (data not
shown) did not induce NORE1A cleavage. None of the extracts
of normal tissues were capable of NORE1A cleavage (Figure 4C,
lanes 3, 5, 7 and 9).
Discussion
To the best of our knowledge, proteolysis of RASSF family
tumor suppressors NORE1A and RASSF1A by calpains has not
been described previously.
Calpains are family of calcium-dependent cysteine proteases.
Several isoforms of mammalian calpains are known to date
(calpains 1–16); the majority of them are ubiquitously expressed
[19,20]. Since NORE1A is proteolyzed by extract of two cell
lines, H358 and H460, and RASSF1A is proteolyzed only by the
extract of H358 cells, different calpain isoforms might be
involved in proteolysis of NORE1A and RASSF1A.
Calpains are involved in regulatory cleavage of a number of
substrates during cell adhesion, spreading, migration, differen-
tiation, apoptosis and autophagy [19–21]. Calpains are also
involved in regulation of cancer cell growth. Inhibition of
calpain activity by cell-permeable inhibitors suppressed anchor-
age-independent growth of cells transformed by Src, Jun, Myc,
Ki-Ras and Fos oncogenes [22]. However, in other studies
calpain inhibition promotes anchorage-independent growth of
NIH 3T3 cells [23]. Calpain activity was significantly higher in
breast cancer samples relative to normal matching controls [24]
and calpeptin, a cell-permeable specific inhibitor of calpain,
inhibited growth of estrogen receptor-positive breast cancer cells
[25].
Calpains are involved in cleavage and inactivation of tumor
suppressors such as p53, its relative p73, NF2/merlin, and
cyclin-dependent kinase inhibitors p19INK4d[26] and p27Kip1
[27–30]. In tumor cells with wildtype p53, inhibition of calpain
increased p53 level and enhanced apoptosis [31]. The Rb tumor
suppressor is cleaved by calpain during tumor necrosis factor-
alpha (TNFa)-induced apoptosis in HeLa cells. Calpain inhib-
itors stabilized Rb; mouse embryo fibroblasts with targeted
disruption of a gene encoding calpain regulatory subunit CAPN4
have elevated Rb level and showed resistance to TNFa-induced
apoptosis in comparison with wild-type cells [32]. The E7
transforming protein of the human papilloma virus (HPV)
induces calpain-mediated Rb cleavage in vitro and in vivo; the
cleaved Rb was deficient in inducing growth arrest in SAOS-2
cells. Calpain inhibitors interfered with the E7-mediated
degradation of Rb and reduced the viability of HPV-transformed
cells [33].
Our finding that activity capable of NORE1A proteolysis
as found not only in cell lines but in human tumors argues
against the hypothesis that calpain cleavage of NORE1A and
perhaps RASSF1A is an artifact of tissue culture. The calpain-
mediated cleavage of NORE1A and RASSF1 tumor suppres-
sors might be a mechanism by which some human tumors
escape growth and tumor suppression. Further studies will be
needed to address the question whether inhibition of this
cleavage might induce re-expression of NORE1A and
RASSF1A proteins with subsequent growth arrest or cell death
in tumor cells.
Figure 3. A: Cleavage of NORE1A and RASSF1A requires
calcium and is sensitive to calpain inhibitors. NORE1A, tagged
N-terminally with the FLAG tag, was expressed in HEK293 cells and
adsorbed on FLAG beads (lanes 1–4). RASSF1A, tagged N-terminally
with the FLAG tag, was expressed as described in Figure 1 (lanes 5–8).
Equal amount of beads containing NORE1A, or RASSF1A were
incubated for 30 min at 37uC with H358 cells extract with no additions
(lanes 2, 6) or with 1 mM of calpain inhibitor ALLN (lanes 3, 7) or with
50 mM EDTA (lanes 4, 8). NORE1A and RASSF1A, eluted from beads with
the FLAG peptide without cleavage, was used as controls (lanes 1 and 5,
respectively). After incubation, NORE1A-containing beads were exten-
sively washed. Samples were subjected to gel electrophoresis followed
by Western blotting with anti-FLAG antibodies. Asterisk denoted IgG
heavy chain eluted from FLAG beads. B, Cathepsin B and Cathepsin
K are not responsible for NORE1A cleavage by H358 and H460
cell lysates: NORE1A, tagged N-terminally with the FLAG tag, was
expressed as described in Methods and adsorbed on FLAG beads. Equal
amounts of NORE1A were incubated for 30 min at 37uC with H358 cells
extract (lanes 2–5) or H460 cell extract (lanes 6–9) with no additions
(lanes 2, 6) or with ALLN (1 mM, lanes 3, 7) or with inhibitor of Cathepsin
B (10 mM, lanes 4, 8) or with inhibitor of Cathepsin K (2 mM, lanes 5, 9).
NORE1A eluted from beads with the FLAG peptide was used as control
(lane 1). After incubation, beads were extensively washed and proteins
retained on them were subjected to gel electrophoresis followed by
Western blotting with anti-FLAG antibodies.
doi:10.1371/journal.pone.0003997.g003
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Materials and Methods
Cell Lines and Transfection
H358, H460, H157, HEK293 and A549 cells (ATCC,
Manassas, VA) were cultured in high-glucose DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum in a 5%
CO2 atmosphere at 37uC. Plasmids encoding NORE1A or
RASSF1A were transfected into 293 cells with Lipofectamine
agent (Invitrogen) as described previously [8,34].
Reagents and Plasmids
Plasmids encoding NORE1A and RASSF1A tagged N-
terminally with the FLAG tag were described previously [8]. All
other constructs were prepared using standard molecular biology
techniques and verified by sequencing. ALLN calpain inhibitor
(cat # 208719), Cathepsin B inhibitor II (cat # 219385) and
Cathepsin K inhibitor I (cat # 219377) were from EMD
Biosciences. The monoclonal anti-NORE1A antibody 10F10
and all other reagents were previously described by Moshnikova
et al. [8].
Preparation of cell extracts and in vitro cleavage
Cells growing in tissue culture were extracted in the Buffer A:
30 mM HEPES, pH 7.4, 20 mM KCl, 1 mM NaVO4, 20 mM
NaF, 20 mM b-glycerophosphate, 7.5 mM MgCl2, 1% Triton X-
100, 2 mM EGTA, 0.1% 2-mercaptoethanol and protease
inhibitor cocktail for mammalian cells and tissues, Sigma Cat #
P8340 at 0.3% (v/v). Cell extracts were clarified by centrifugation
at 16,1006g for 40 minutes at 4uC. Protein concentration was
measured and aliquots of each extract containing equal amounts
of protein was incubated with FLAG-tagged NORE1A or
RASSF1A proteins expressed in 293 cells, purified on FLAG
beads and eluted with 0.1 mg/ml of FLAG-peptide solution in
Buffer A as described previously [8]. After thirty minute
incubation at 37uC, electrophoretic sample buffer was added to
16 concentration, samples were boiled and subjected to Western
blotting.
Immunoprecipitation and Western Blot Analysis
Transfected 293 cells were lysed in buffer A and NORE1A and
RASSF1A were immunoprecipitated from cell extract as described
previously [8,34]. In some experiments, NORE1A and RASSF1A
were eluted from FLAG-beads as described above.
Human Tumor samples
Anonymized specimens of human lung tumors and noncan-
cerous tissue surrounding the tumor were procured using
University of Virginia Biorepository and Tissue Research
Facility. The procurement was done according to the institu-
tional IRB policy. Tissues were extracted into buffer A and
clarified by centrifugation and the extracts were used for in vitro
cleavage.
Author Contributions
Conceived and designed the experiments: SK AK. Performed the
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Figure 4. A, The addition of a calpain inhibitor ALLN to cultured cells prevents NORE1A degradation: NORE1A was re-expressed in H157
cells (lanes 1, 6), H358 cells (lanes 3, 8) and H460 cells (lanes 5, 10) using a vector with a drug-resistance marker with subsequent selection for the
drug. Lanes 2, 7 represent H358 parental cells and lanes 4, 9 - H460 parental cells. Cells were cultured for 3 days without inhibitors (top panel) or with
1 mM ALLN (bottom panel). Cell extracts, equalized by a-tubulin, were probed with 10F10 antibody by Western Blotting. At 1 mM concentration ALLN
did not induce apoptotic response in H358 and H460 cells (data not shown). B, NORE1A expression at the mRNA level in H358 and H460
cells: NORE1A cDNA was re-expressed in H358 and H460 cells using a vector with a drug-resistance marker. Total mRNA was extracted from pools of
drug-resistant cells emerged after selection as indicated and analyzed by RT-PCR for NORE1A expression. Note that these cells did not express
NORE1A protein (Fig 4A, lanes 3 and 5). NORE1A, cDNA of vector used for transduction was included as a positive control. M, DNA molecular weight
markers. C: Extracts of human tumors are capable of degrading NORE1A. Human lung tumors from patients 3, 9, 10 and 8 and matching
normal lung tissues were extracted into buffer for cell extraction and normalized by total amount of cellular protein. Equal amount of extracts from
tumors (T) and normal tissues (N) were mixed with FLAG-tagged NORE1A, immunopurified as described in Methods. After thirty minute incubation at
37uC, electrophoretic sample buffer was added to 16 concentration, samples were boiled and subjected to Western blotting with anti-FLAG
antibodies. As positive control for NORE1A degradation, NORE1A incubated with H460 cell extract (lane 2) was used.
doi:10.1371/journal.pone.0003997.g004
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